INS and type 2 diabetes mellitus: Ludvik Ludvik B B Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial Lancet Lancet 2021 2021 398 398 10300 10300 583 583 598 598 10.1016/S0140-6736(21)01443-4 10.1016/S0140-6736(21)01443-4 supplied-pmid 34370970?